![Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab](https://bmjopen.bmj.com/content/bmjopen/8/2/e019007/F1.large.jpg)
Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab
Slobodan Gigov on LinkedIn: White Paper: Bispecific Antibody PK and ADA Bioanalysis: An Experienced…
![Incidence of Inflammatory Bowel Disease Events in Adalimumab (HUMIRA) Clinical Trials Across Indications - ACR Meeting Abstracts Incidence of Inflammatory Bowel Disease Events in Adalimumab (HUMIRA) Clinical Trials Across Indications - ACR Meeting Abstracts](https://acrabstracts.org/wp-content/uploads/2016/09/Paper_57346_abstract_80810_0.jpg)
Incidence of Inflammatory Bowel Disease Events in Adalimumab (HUMIRA) Clinical Trials Across Indications - ACR Meeting Abstracts
![Streamline Immunogenicity Assay Development: Expedite Research Workflows by Understanding the Issues with ADA Assays | Sword Bio Streamline Immunogenicity Assay Development: Expedite Research Workflows by Understanding the Issues with ADA Assays | Sword Bio](https://swordbio.com/wp-content/uploads/Expanded-FDA-ADA-Multi-Tiered-Approach-819x1024.jpg)
Streamline Immunogenicity Assay Development: Expedite Research Workflows by Understanding the Issues with ADA Assays | Sword Bio
![Antibodies | Free Full-Text | Understanding Inter-Individual Variability in Monoclonal Antibody Disposition Antibodies | Free Full-Text | Understanding Inter-Individual Variability in Monoclonal Antibody Disposition](https://pub.mdpi-res.com/antibodies/antibodies-08-00056/article_deploy/html/images/antibodies-08-00056-g001.png?1577721042)
Antibodies | Free Full-Text | Understanding Inter-Individual Variability in Monoclonal Antibody Disposition
![Gene therapy for adenosine deaminase–deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans - ScienceDirect Gene therapy for adenosine deaminase–deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497120461981-gr1.jpg)
Gene therapy for adenosine deaminase–deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans - ScienceDirect
![Assessment of immunogenicity and drug activity in patient sera by flow-induced dispersion analysis | Scientific Reports Assessment of immunogenicity and drug activity in patient sera by flow-induced dispersion analysis | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-08682-3/MediaObjects/41598_2022_8682_Fig1_HTML.png)
Assessment of immunogenicity and drug activity in patient sera by flow-induced dispersion analysis | Scientific Reports
![Mitigating target interference in bridging immunogenicity assay with target-blocking reagents and mild basic pH | Bioanalysis Mitigating target interference in bridging immunogenicity assay with target-blocking reagents and mild basic pH | Bioanalysis](https://www.future-science.com/cms/10.4155/bio-2018-0187/asset/images/medium/figure3.gif)
Mitigating target interference in bridging immunogenicity assay with target-blocking reagents and mild basic pH | Bioanalysis
![Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency - ScienceDirect Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497121010612-grabsf1.jpg)
Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency - ScienceDirect
![Study overview. A Clinical trials were found using clinicaltrials.gov... | Download Scientific Diagram Study overview. A Clinical trials were found using clinicaltrials.gov... | Download Scientific Diagram](https://www.researchgate.net/publication/374418223/figure/fig1/AS:11431281205484396@1700277389945/Study-overview-A-Clinical-trials-were-found-using-clinicaltrialsgov-and-sought-for.png)
Study overview. A Clinical trials were found using clinicaltrials.gov... | Download Scientific Diagram
![Frontiers | The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies Frontiers | The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies](https://www.frontiersin.org/files/Articles/540270/fimmu-11-01951-HTML/image_m/fimmu-11-01951-g001.jpg)
Frontiers | The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies
![Gene therapy clinical trial for adenosine deaminase-severe combined... | Download Scientific Diagram Gene therapy clinical trial for adenosine deaminase-severe combined... | Download Scientific Diagram](https://www.researchgate.net/publication/328126707/figure/fig3/AS:678794197225474@1538848556498/Gene-therapy-clinical-trial-for-adenosine-deaminase-severe-combined-immunodeficiency.png)